Panel Informativity Optimizer: An R Package to Improve Cancer Next-Generation Sequencing Panel Informativity.


Journal

The Journal of molecular diagnostics : JMD
ISSN: 1943-7811
Titre abrégé: J Mol Diagn
Pays: United States
ID NLM: 100893612

Informations de publication

Date de publication:
06 2022
Historique:
received: 17 07 2021
revised: 22 12 2021
accepted: 09 03 2022
pubmed: 16 4 2022
medline: 15 6 2022
entrez: 15 4 2022
Statut: ppublish

Résumé

Mutation detection by next-generation sequencing is routinely used for cancer diagnosis. Selecting an optimal set of genes for a given cancer is not trivial as it has to optimize informativity (ie, the number of patients with at least one mutation in the panel), while minimizing panel length to reduce sequencing costs and increase sensitivity. We propose herein Panel Informativity Optimizer (PIO), an open-source software developed as an R package with a user-friendly graphical interface to help optimize cancer next-generation sequencing panel informativity. Using patient-level mutational data from either private data sets or preloaded data set of 91 independent cohorts from 31 different cancer types, PIO selects an optimal set of genomic intervals to maximize informativity and panel size in a given cancer type. Different options are offered, such as the definition of genomic intervals at the gene or exon level and the use of optimization strategy at the patient or patient per kilobase level. PIO can also propose an optimal set of genomic intervals to increase informativity of custom panels. A panel tester function is also available for panel benchmarking. Using public databases, as well as data from real-life settings, we demonstrate that PIO allows panel size reduction of up to 1000 kb, and accurately predicts the performance of custom or commercial panels.

Identifiants

pubmed: 35427780
pii: S1525-1578(22)00079-4
doi: 10.1016/j.jmoldx.2022.03.005
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

697-709

Informations de copyright

Copyright © 2022 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Auteurs

Vincent Alcazer (V)

Department of Clinical Hematology, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, France; Department of Biological Hematology, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, France. Electronic address: vincent.alcazer@chu-lyon.fr.

Pierre Sujobert (P)

Department of Biological Hematology, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, France. Electronic address: pierre.sujobert@chu-lyon.fr.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH